Grantmaking public charityEIN 854079051
INTERNATIONAL FOXP1 FOUNDATION
MENDENHALL, PA 19357
Total Assets
$291K
FY 2024
Annual Giving
$123K
FY 2024
Grants Made
2
FY 2024
Avg Grant
$62K
FY 2024
Grant Range
—
Typical
Deadlines
—
Applications
Programs & Activities
Program 1
$73KFunctional restoration of foxp1 haploinsufficiency using aav-mediated gene rescue in the brain-understanding foxp1 function in the mouse brain is crucial to develop effective therapeutics for foxp1 syndrome in humans. In this project, we will use a mouse model that mimics the genetic basis of many forms of foxp1 syndrome, where only one out of the two functional copies of foxp1 gene is present. We will perform intracerebroventricular (icv) injections of a unique adeno associated virus (aav) called aav9 and/or its modified and improvised version (aav-php.eb) at an early developmental stage to restore foxp1 expression in the brains of these mice. In this strategy, foxp1 will be re-expressed under the control of the human synapsin 1 promoter, ensuring neuron specific expression. We will then examine whether foxp1 gene replacement can correct behavioral deficits in the mice. If successful, we will extend the gene restoration to later developmental time points to determine a potential critical window of gene replacement therapy in this mouse model. Results from this project should provide fundamental knowledge about the feasibility of foxp1 gene therapy in humans and form the basis for future clinical trials.
Program 2
$62KTesting a potential treatment for foxp1 syndrome in striatal organoids derived from individuals with pathogenic foxp1 variants -dr. Frhlich and prof. Rappold at the institute of human genetics in heidelberg, germany have discovered that murine foxp1 haploinsufficiency leads to mitochondrial dysfunction in the striatum and altered expression of striatum-specific phosphodiesterase 10a (pde10a), an enzyme that plays a crucial role in the regulation of basal ganglia circuits. Specific inhibition of pde10a with mp-10 significantly improved the existing behavioral deficits in these animals. Working with organoids has significant implications for a safe and humane testing of new drugs, particularly when organoids are grown from a patient's own cells. In the planned project, ipsc lines derived from foxp1 patient and control cells will be used and differentiated into striatal organoids to investigate whether mitochondrial dysfunction and pde10a dysregulation can also be found in human cells. In addition, it will be analyzed how the administration of mp-10 affects gene expression and signaling pathways in striatal medium spiny neurons and whether the drug improves mitochondrial function.
Focus Areas
Financial Snapshot
2024 filing
Total Revenue
$339K
Total Expenses
$229K
Top Recipients
2 grants
Grant Size Distribution
2 grants
Geographic Focus
2 states
Ready to work on a proposal for INTERNATIONAL FOXP1 FOUNDATION?
Open a draft with this funder pre-selected. Add guidelines when you have them.
Related funders in Pennsylvania
INTERNATIONAL FEDERATION FOR ADIPOSE THERAPEUTICS
Pittsburgh, PA
SWEET WATER TRUST
KENNETT SQUARE, PA · $23.1M in grants
EQT FOUNDATION
CANONSBURG, PA · $6.3M in grants
THE POMEROY FAMILY FOUNDATION
MECHANICSBURG, PA · $2.3M in grants
JAMES DUNCAN PHILLIPS FUND FOR HARVARD
PITTSBURGH, PA · $1.7M in grants
GERMESHAUSEN FOUNDATION INC
WAYNE, PA · $1.2M in grants
THE NARARO FOUNDATION
PHILADELPHIA, PA · $797K in grants
THE ROBERTS FOUNDATION
PHILADELPHIA, PA · $710K in grants
Track INTERNATIONAL FOXP1 FOUNDATION
Get an email when Grantivo has new data for INTERNATIONAL FOXP1 FOUNDATION, such as a fresh IRS filing, updated financials, or newly reported grants. No account needed.
Free. Unsubscribe anytime. Or create an account to draft an application.